Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Birk Poller

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 26, 2021
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as PerpetratorH Markus Weiss, Thomas Langenickel, Meredith Cain, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 12, 2023
Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro StudiesAlexander David James, Kenneth Kulmatycki, Birk Poller, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
Journal of Neurochemistry|November 18, 2008
The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studiesBirk Poller, Heike Gutmann, Stephan Krähenbühl, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 3, 2022
Time matters - <i>in vitro</i> cellular disposition kinetics help rationalizing cellular potency disconnectsBirk Poller, Sophie Werner, Norbert Domange, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 6, 2022
Novel insights into bile acid detoxification via CYP, UGT and SULT enzymesVlasia Kastrinou Lampou, Birk Poller, Felix Huth, et al.
Archives of Toxicology|November 14, 2024
Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanismsVlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
International Journal of Cancer|February 26, 2011
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministrationSeng Chuan Tang, Jurjen S Lagas, Nienke A G Lankheet, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2022
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug DispositionBirk Poller, David Pearson, Luc Alexis Leuthold, et al.
Pulmonary Pharmacology & Therapeutics|June 14, 2019
Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypesBirk Poller, Ralph Woessner, Avantika Barve, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 26, 2021
Clinical Investigation of Metabolic and Renal Clearance Pathways Contributing to the Elimination of Fevipiprant Using Probenecid as PerpetratorH Markus Weiss, Thomas Langenickel, Meredith Cain, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 12, 2023
Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]iptacopan in Healthy Male Volunteers and in In Vivo and In Vitro StudiesAlexander David James, Kenneth Kulmatycki, Birk Poller, et al.
Clinical and Translational Science|August 25, 2021
Novel Bruton's Tyrosine Kinase inhibitor remibrutinib: Drug-drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modelingFelix Huth, Hilmar Schiller, Yi Jin, et al.
Journal of Neurochemistry|November 18, 2008
The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studiesBirk Poller, Heike Gutmann, Stephan Krähenbühl, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 3, 2022
Time matters - <i>in vitro</i> cellular disposition kinetics help rationalizing cellular potency disconnectsBirk Poller, Sophie Werner, Norbert Domange, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|December 6, 2022
Novel insights into bile acid detoxification via CYP, UGT and SULT enzymesVlasia Kastrinou Lampou, Birk Poller, Felix Huth, et al.
Archives of Toxicology|November 14, 2024
Drug-induced cholestasis (DIC) predictions based on in vitro inhibition of major bile acid clearance mechanismsVlasia Kastrinou-Lampou, Raquel Rodríguez-Pérez, Birk Poller, et al.
International Journal of Cancer|February 26, 2011
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministrationSeng Chuan Tang, Jurjen S Lagas, Nienke A G Lankheet, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 4, 2022
Human Pharmacokinetics of LYS006, an Oral Leukotriene A4 Hydrolase Inhibitor Displaying Target-Mediated Drug DispositionBirk Poller, David Pearson, Luc Alexis Leuthold, et al.
Pulmonary Pharmacology & Therapeutics|June 14, 2019
Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypesBirk Poller, Ralph Woessner, Avantika Barve, et al.
Pageof 4